Solid Biosciences (SLDB) Reiterated at Market Outperform by Citizens After FDA Alignment
Tweet Send to a Friend
Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $15.00 price target on Solid Biosciences (NASDAQ: SLDB).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
